Antiplatelet therapy plays a pivotal role in modern management of coronary artery disease and use of clopidogrel has facilitated the emergence of intravascular stenting as common cardiological practice. However, clopidogrel responsiveness is heterogeneous within the population, with a sizable proportion seemingly non-responsive to its antiplatelet effects and at higher risk of cardiovascular events as a result [1, 2].
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.